Pharmaceutical News

RSS

Experts offer myth-busting advice to fight against spring allergies

Millions of Americans sneeze and wheeze March through June when they use misinformation to manage their spring allergies.

27 Feb 2011

Samsung enters strategic partnership with Quintiles to support biopharmaceuticals market

Samsung Electronics Co., Ltd., the world's largest electronics company, and its affiliated companies have entered into a strategic partnership with Quintiles, the world's leading pharmaceutical services company, to support Samsung's entry into the biopharmaceuticals market, Quintiles announced today.

27 Feb 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Vaccine lawsuit rejected by Supreme Court

The U.S. Supreme Court ruled on Tuesday against the parents of Hannah Bruesewitz, 18, who suffered seizures and permanent brain damage after receiving a diptheria-tetanus-pertussis (DTP) vaccine in 1993. The Bruesewitz family had sued Wyeth who was then the parent company of the maker of the DTP vaccine that Hannah received as an infant.

27 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

Takeda receives Japanese approval for additional indications for NESINA

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for "NESINA®" (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare.

25 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

Symposium examines Bruesewitz vs. Wyeth Supreme Court case

A March 29 symposium at the New York Academy of Sciences, "Vaccines Under the Gun: Politics, Science, Media and the Law," will feature a presentation by Daniel J. Thomasch, JD, national lead trial counsel for Wyeth, who was involved in the case decided by the Supreme Court yesterday in which the justices rejected a lawsuit claiming injury from a Wyeth vaccine.

25 Feb 2011

Patients presented to ED with adverse drug events are more costly to health care system

Patients who suffer an adverse medical event arising from the use or misuse of medications are more costly to the health care system than other emergency department patients, say physicians and research scientists at Vancouver General Hospital and UBC.

25 Feb 2011

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

25 Feb 2011

Signal files complaint against Med Biogene and Precision Therapeutics in Supreme Court

Med Biogene Inc., a Vancouver-based life sciences company, has been charged with fraud, and Pittsburgh-based Precision Therapeutics, Inc., was charged with tortious interference in an amended complaint filed today by Signal Genetics in Supreme Court for the County of New York.

25 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

New 'closed-loop' system can provide tightly controlled anesthesia in patients undergoing surgery

A new 'closed-loop' system can precisely adjust levels of anesthetics and analgesic drugs in patients undergoing surgery, reports a study in the March issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

25 Feb 2011

Celgene, Elan enter settlement and license agreement for ABRAXANE

Elan Corporation plc and Celgene Corporation, today announced that Elan subsidiary Elan PharmaInternational Limited has entered into a settlement and license agreement with Celgene Corporation resolving the patent infringement litigation involving ABRAXANE.

24 Feb 2011

FDA approves sBLA for CSL's Hizentra to treat PI

CSL Behring announced today that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra, Immune Globulin Subcutaneous, 20% Liquid, from 24 months to 30 months.

24 Feb 2011

Supreme Court raises the bar for suits against vaccine producers

The decision, announced Tuesday, will make it harder for parents who maintain that their children were injured by vaccines to file lawsuits against drug makers. Public health advocates say the ruling will help maintain the nation's vaccine supply levels.

24 Feb 2011

Steroid administration may impact immune system in children with asthma

Children experiencing an asthma attack who are treated with a short burst of oral steroids may have a transient depression of immune response according to a new study led by Universit- de Montr-al.

24 Feb 2011

Study examines several homicides involving anesthetic drugs, outlines anesthesiologists' experiences

A study published in March's issue of Anesthesiology examines several homicides involving anesthetic drugs and calls on anesthesiologists to assist in the investigation and prosecution of criminals who divert and kill with these drugs.

24 Feb 2011